Ethics approval and consent to participate
Ethics approval was obtained from appropriate Institutional Ethics Committees/Institutional Review Boards: Royal Melbourne Hospital, Melbourne, Victoria, Australia; Ethics Review Committee, Central Sydney Area Health Service, Camperdown, Australia; Health Sciences Centre, University of Western Ontario, London, Ontario, Canada; Ottawa General Hospital, Ottawa, Ontario, Canada; Office of Research Services, Clinical Screening Committee for Research Involving Human Subjects, University of British Columbia, Vancouver, British Columbia, Canada; Forskningsetikkommittén I Lund/Malmö, Lund University Hospital, Lund, Sweden; Independent Review Board, Amsterdam, Netherlands; Newcastle & North Tyneside Health Authorities, Newcastle upon Tyne, UK; Ethical Committee, University Hospital, Nottingham, UK; United Medical and Dental Schools, Division of Pharmacological Sciences, Department of Clinical Pharmacology, St. Thomas’s Hospital, London, UK; Central Oxford Research Ethics Committee, Headington, Oxford, UK; Commissie voor Medische Ethiek/Klinisch Onderzoek, UZ Leuven, Leuven, Belgium; Limburgs Universitair Centrum, Diepenbeek, Belgium; Commission d’Ethique Hospito-Facultaire, Université catholique de Louvain, Louvain-la-Neuve, Belgium; Helsinki University Hospitals Ethical Committee, Helsinki, Finland; Joint Commission on Ethics of the Turku University Central Hospital, Turku University Central Hospital, Turku, Finland; Ethik-Kommission de Medizinischen Fakultät der Universität Würzburg, Würzburg University, Würzburg, Germany; Ethik-Kommission des Departementes für Innere Medizin, Kantonsspital Basel, Basel, Switzerland; Academisch Zienkenhuis Vrije Univeriteit Commissie Voor Medische Ethiek/Klinisch Onderzoek, Leuven, Belgium; Medisch Ethische Commissie, Academisch Ziekenhuis Rotterdam, Rotterdam, Netherlands; St. George’s Healthcare NHS Trust, St George’s Hospital, London, UK; and Commission d’Ethique du Département de Médicine, Hôpitaux Universitaires de Genève, Geneva, Switzerland. All patients gave written informed consent.
A Traboulsee has acted as a consultant for Biogen, Genzyme, Roche, and Teva, and is Principal Investigator on clinical trials for Biogen, Chugai, Genzyme, and Roche.
D Li is the Director of the University of British Columbia MS/MRI Research Group, which has been contracted to perform central analysis of MRI scans for therapeutic trials with Genzyme, Hoffmann-La Roche, Merck Serono, Nuron, Perspectives, and Sanofi-Aventis. He has acted as a consultant to Vertex Pharmaceuticals; has served on scientific advisory boards for Novartis, Nuron, and Roche; has served on a data and safety advisory board for Opexa; and has received research funding from the Canadian Institute of Health Research and Multiple Sclerosis Society of Canada.
M Cascione has received funding/honoraria for research, consultation, and speakers bureau participation from Acorda, Bayer HealthCare, Biogen, EMD Serono, Inc., Genentech, Genzyme/Sanofi, Novartis, Pfizer, Roche, and Teva Pharmaceuticals.
J Fang was an employee of EMD Serono, Inc., Rockland, MA, USA (a business of Merck KGaA, Darmstadt, Germany) at the time of writing.
F Dangond is an employee of EMD Serono, Inc., Billerica, MA, USA (a business of Merck KGaA, Darmstadt, Germany).
A Miller has received research support from Biogen, Sanofi-Genzyme, Mallinckrodt (Questcor), Novartis, and Roche/Genentech. He has acted as a consultant for Accordant Health Services (Caremark), Acorda Therapeutics, Alkermes, Biogen, EMD Serono, Sanofi Genzyme, GlaxoSmithKline, Mallinckrodt (Questcor), Novartis, and Roche/Genentech. He has served on the speakers bureau for Biogen, Genentech, and Sanofi Genzyme for unbranded disease awareness programs only.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.